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Background 
The role of immuno-modulating diets (IMD’s) in critically ill 
patients is controversial.      
Methods 
Objective: The goal of this meta-analysis was to determine 
the impact of IMD's on hospital mortality, nosocomial 
infections and length of stay (LOS) in critically ill patients. 
Outcome was stratified according to type of IMD and patient 
setting. 
Data Sources: MEDLINE, Embase, Cochrane Register of 
Controlled Trials. 
Study Selection: RCT's that compared the outcome of 
critically ill patients randomized to an IMD or a control diet. 
Data Synthesis: Twenty-four studies (with a total of 3013 
patients) were included in the meta-analysis; 12 studies 
included ICU patients, 5 burn patients and 7 trauma 
patients. Four of the studies used formulas supplemented 
with arginine, two with arginine and glutamine, nine with 
arginine and fish oil (FO), two with arginine, glutamine and 
FO, six with glutamine alone and three studies used a 
formula supplemented with FO alone. Overall IMD's had no 
effect on mortality or LOS, but reduced the number of 
infections (OR 0.63; 95% CI 0.47-0.86, P = 0.004, I
2 = 
49%). Mortality, infections and LOS were significantly lower 
only in the ICU patients receiving the FO IMD (OR 0.42, 
95% CI 0.26-0.68; OR 0.45, 95% CI 0.25-0.79 and WMD -
6.28 days, 95% CI -9.92 to -2.64, respectively). 
Conclusions 
An IMD supplemented with FO improved the outcome of 
medical ICU patients (with SIRS/sepsis/ARDS). IMD’s 
supplemented with arginine with/without additional 
glutamine or FO do not appear to offer an advantage over 
standard enteral formulas in ICU, trauma and burn patients. 
 
Commentary 
The widespread recognition that critical illness is 
characterized as a state of immunosuppression and 
inflammation has lead to the development of nutritional 
support products or interventions designed to enhance the 
host immune response and/or suppress inflammation. 
Importantly, the use of immune modulating diets (IMD) in 
critically ill patients needs to be translated into 
improvements in clinically relevant outcomes such as 
infectious morbidity, mortality and length of stay. While 
IMD’s containing immunonutrients such as glutamine, 
arginine, and omega-3 fatty acids are conceptually 
appealing, data from multiple individual trials and several 
meta-analyses have failed to produce convincing evidence 
that important clinical outcomes are favorably affected in 
critically ill patients [2]. Prior quantitative reviews of 
immunonutrition have been confounded by grouping 
different immune enhancing formulas and different types of 
patients together, introducing heterogeneity and perhaps 
masking treatment effects [3-7]. 
In the current study, Marik and Zaloga [1] performed a 
meta-analysis of published randomized controlled trials of 
IMD’s in critically ill patients to test the hypothesis that 
effects of IMD’s might be apparent if the analysis accounted 
for the type of IMD formulation used and the subgroup of 
critically ill patients in which the IMD’s were employed. Their 
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search strategy yielded a total of 24 randomized controlled 
trials with 12 of these studies identified as occurring in an 
ICU setting, 5 studies performed in burn patients and 7 
studies performed in trauma patients. Commercially 
available immune enhancing enteral diets were employed in 
these studies and for the purposes of analysis, were 
categorized by the investigators as containing arginine 
alone; arginine and glutamine; arginine and fish oil (FO); 
arginine, glutamine and FO; glutamine alone; and FO alone. 
The clinical outcomes of hospital mortality (N = 23 studies), 
new infections (N = 21 studies) and hospital length of stay 
(LOS) (N = 13) were analyzed. When available, the 
outcomes were assessed on an intention to treat basis.  
The combined analysis revealed no effect of IMD’s on 
mortality or LOS. However, IMD’s were favored in reducing 
new infections. Subgroup analysis by type of IMD revealed 
that only the ICU subgroup receiving FO alone (N = 3 
studies) had significant effects on all study outcomes 
(mortality, secondary infections and LOS). Subgroup 
analysis by patient category revealed a reduction in 
secondary infections and LOS in ICU patients that was not 
apparent if the analysis excluded patients who received FO 
alone. Effects in other subgroups by IMD or patient group 
were not evident. The authors concluded that FO IMD’s 
improved outcomes in medical ICU patients with SIRS, 
sepsis, or ARDS. 
While the authors recognized some of the inherent 
weaknesses in their meta-analysis including the small 
numbers of studies for subgroups based on type of IMD, an 
explicit analysis of the quality of the studies included in the 
review would have been helpful. The authors’ main findings 
were based on the results of three clinical trials, each with 
methodological limitations. In the first study, the effect of an 
enteral diet consisting of FO and antioxidant vitamins in 
patients with ARDS was evaluated in a randomized double-
blind multi-center study [8]. This study was not powered to 
detect differences in mortality, nor was it specifically 
designed to evaluate new infections. In the intention to treat 
analysis, there was no difference in hospital mortality, 
hospital length of stay, or the development of infectious 
complications. The second study [9] was a double-blind 
single-center study of the same FO and antioxidant vitamin 
supplemented enteral diet in patients with severe sepsis or 
septic shock with a primary outcome of all cause 28-day 
mortality. While a difference in 28-day mortality was 
suggested by the data, an intension to treat analysis was 
not performed and infectious morbidity and hospital length 
of stay were not reported. The third study [10] evaluated the 
same enteral formulation in a single-center study of patients 
with acute lung injury. This study was not blinded and 
evaluated oxygenation and respiratory compliance as 
primary outcomes. In this study, there was no difference in 
hospital length of stay or survival and infectious morbidities 
were not reported. Given the variability in study design, 
methods, patient populations, and outcome variables 
tested, the conclusions drawn from the combination of these 
three studies should be carefully weighed.  
These results highlight the complexities of immunonutrition 
in critically ill patients and lend further support to an 
emerging paradigm shift from immunonutrition to 
pharmaconutrition, where specific nutrients are evaluated 
independent of providing calories and protein to the patient  
[4]. The data from this review and the others preceding it 
leave us hopeful that it may be the last meta-analysis of 
immunonutrition using commercially produced products 
containing multiple potential immunonutrients. As suggested 
by Jones and Heyland [2],
  future studies should be 
designed similar to drug trials. That is to say that the effect 
of individual immunonutrients should be assessed 
independent of standard nutritional support and clinically 
relevant outcomes evaluated in well-defined populations of 
critically ill patients. 
Recommendation 
In summary, while this meta-analysis suggests a potentially 
beneficial effect of fish oil based IMD’s in a subset of 
critically patients with SIRS, sepsis, or ARDS, the data upon 
which these conclusions are drawn are too weak to endorse 
a strong recommendation for use in these populations. The 
question of whether fish oil or any other potentially immune-
modulating nutrient has real and measurable value in 
critically ill patients will depend largely on data drawn from 
well-designed and adequately powered trials based on the 
emerging concept of pharmaconutrition. 
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